Thymosin Alpha 1

FDA APPROVAL PENDING

Well Studied

Longevity

Immunity

Longevity

Thymosin Alpha 1

Immunity

Amino acid sequence

28

Amino acids

3da

Molecular weight

Peptide

Type

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

Top researched benefits

Overview of Thymosin Alpha 1

Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

Immunity

  • FDA orphan designation for DiGeorge syndrome; restores T-cell function.
  • Improved antibody responses in elderly and hemodialysis patients (H1N1, COVID-19).
  • Restores CD4+ counts and reduces opportunistic infections.

Inflammation

  • Reduces pro-inflammatory cytokines TNF-α, IL-1β, IL-6 by 40-60%.
  • Enhanced antiviral efficacy when combined with interferon.
  • Helps manage inflammatory autoimmune conditions.

Recovery

  • Restores immune function after surgical stress.
  • Manages immune suppression from intense training.

Antiaging

  • Supports thymus gland function with aging.
  • Delays age-related immune decline in elderly populations.

Storage

Use immediately after reconstitution or refrigerate up to 2 hours

Frequency

2x weekly (e.g., Monday and Thursday) for standard immune support

Typical Dose

1.6mg per injection (standard dose across all protocols)

Cycle Duration

6 months continuous for therapeutic protocols

Chemical Makeup

Key benefits

Primary FDA-studied route with extensive clinical validation

Maximum immune modulation through systemic circulation

Established dosing from 35+ countries of clinical use

Exceptional safety profile (<1% serious adverse events)

Reduces pro-inflammatory cytokines 40-60%

Approved in 35+ countries

Community interest

This peptide is still gaining traction in the community.

Synthetic Thymic Hormone | Immune System Modulator

This overview is informational and based on aggregated descriptions from studies and user reports.

Was it helpful?Yes

Thymosin Alpha 1 Molecular Information

View the scientifc details of Thymosin Alpha 1.

28

Amino Acids

Thymosin Alpha 1

Ser

Ser

Position 1

Asp

Asp

Position 2

Ala

Ala

Position 3

Ala

Ala

Position 4

Val

Val

Position 5

Asp

Asp

Position 6

Thr

Thr

Position 7

Ser

Ser

Position 8

Ser

Ser

Position 9

Glu

Glu

Position 10

Ile

Ile

Position 11

Thr

Thr

Position 12

Thr

Thr

Position 13

Lys

Lys

Position 14

Asp

Asp

Position 15

Leu

Leu

Position 16

Lys

Lys

Position 17

Glu

Glu

Position 18

Lys

Lys

Position 19

Lys

Lys

Position 20

Glu

Glu

Position 21

Val

Val

Position 22

Val

Val

Position 23

Glu

Glu

Position 24

Glu

Glu

Position 25

Ala

Ala

Position 26

Glu

Glu

Position 27

Asn

Asn

Position 28

Amino acid sequence
SerinePosition 1
Aspartic acidPosition 2
AlaninePosition 3
AlaninePosition 4
ValinePosition 5
Aspartic acidPosition 6
ThreoninePosition 7
SerinePosition 8
SerinePosition 9
Glutamic acidPosition 10
IsoleucinePosition 11
ThreoninePosition 12
ThreoninePosition 13
LysinePosition 14
Aspartic acidPosition 15
LeucinePosition 16
LysinePosition 17
Glutamic acidPosition 18
LysinePosition 19
LysinePosition 20
Glutamic acidPosition 21
ValinePosition 22
ValinePosition 23
Glutamic acidPosition 24
Glutamic acidPosition 25
AlaninePosition 26
Glutamic acidPosition 27
AsparaginePosition 28

Molecular Weight

3Da

Chain Length

28Amino Acids

Type

Peptide

Thymosin Alpha 1 Protocols

Subcutaneous injection is the primary route with 90-95% bioavailability. Standard dosing is 1.6mg twice weekly.

GoalDosageFrequencyRoute
Standard immune support1.62 week rangeSubQ
Acute conditions (sepsis)1.62 week rangeSubQ/IM
Cancer/hepatitis support1.62 week rangeSubQ
Maintenance/prevention1.62 week rangeSubQ

Reconstitution Instructions

Materials needed:

Thymosin Alpha 1 lyophilized powderSterile water (1.0mL)Insulin syringesAlcohol swabs

Steps to reconstitute

  1. Clean work surface thoroughly
  2. Add 1.0mL sterile water slowly to lyophilized powder
  3. Inject water down vial side (avoid direct powder contact)
  4. Gently swirl until fully dissolved (never shake)
  5. Final concentration: 1.6mg/mL
  6. Use immediately or refrigerate up to 2 hours

Thymosin Alpha 1 Cycle

The Thymosin Alpha 1 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.

Taking breaks between cycles may help maintain effectiveness and support better overall results.

Week 1-2
Initial immune system activation
Week 2-6
Enhanced immune function, reduced infection risk
Week 6-12
Maximum immunomodulatory benefits
Week 0-0
Sustained immune support with continued use

Dosing tools

Thymosin Alpha 1 Peptide Dosage Calculator

Calculate peptide doses with our visual syringe guide.

0.3mL / 30 units

5 units

0.050 mL

1 mL

2 mL

3 mL

5 mL

Custom

Conversion: 1,000 mcg = 1 mg

Injection Results

Based on your vial and dilution inputs.

Safe concentration range

Thymosin Alpha 1

SINGLE COMPOUND

Volume per injection

0.05

mL

Concentration

10.00

mg/mL

Doses per vial

20

doses

Total injections per vial

20 injections

How it works

Based on a 10 mg Thymosin Alpha 1 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.

Research Purposes Only

These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.

Reference Guide

Dosing Cycle

Peptide
Thymosin Alpha 1
Dosing
1.6mg per injection (standard dose across all protocols)
Dosing Frequency
2x weekly (e.g., Monday and Thursday) for standard immune support
Cycle Duration
6 months continuous for therapeutic protocols
Storage
Use immediately after reconstitution or refrigerate up to 2 hours

Note: Triple agonist; microdose for fewer side effects

Reconstitution Tips

  • Use bacteriostatic water (BAC)contains 0.9% benzyl alcohol for preservation
  • Inject water slowlyaim down the vial wall, not directly onto powder
  • Never shakegently swirl or roll the vial until dissolved
  • Store properlyrefrigerate at 2-8°C after reconstitution
  • Use within 28 daysmost reconstituted peptides remain stable for about 4 weeks
  • Keep sterilealways clean vial tops with alcohol before drawing

Side effects

Contraindications

Organ transplant recipients (risk of graft rejection)

Pregnancy and breastfeeding

Stop signs

Signs of graft rejection in transplant recipients

Persistent injection site reactions or infection signs

Unusual immune system hyperactivity

Severe allergic reactions (rare)

Bad signs

Yellow, brown, or collapsed powder (heat/moisture degradation)Persistent cloudiness or particles post-reconstitutionNon-professional sourcing or unclear labeling
Was it helpful?Yes

Comments

0.0

0 reviews

5

4

3

2

1

No comments yet

Be the first to share your experience. Your review helps others make more informed decisions.

Frequently asked questions

What benefits can peptides offer in research?

Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.

What are some exciting applications of peptides in modern science?

Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.

How do peptides influence health and wellness?

Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.

Where can I find the latest studies on peptide applications?

Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.

Are there any guidelines for using peptides in research?

Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.

What is the difference between peptides and proteins?

Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.

How should peptides be stored?

Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.

Can peptides be taken orally?

Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.

Thymosin Alpha 1Research References

Thymosin Alpha 1 is a well studied compound

4Research references

Thymosin Alpha 1

Thymosin Alpha 1 is a well studied compound

COVID-19 Treatment Study

30% vs 11% mortality reduction in severe cases; lymphocyte restoration.

2020

TESTS Phase 3 Sepsis Trial

1,106 patients; mixed overall results but subgroup benefits in elderly/diabetic populations.

2020

Cytokine Storm Mitigation Study

40-60% reduction in pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

2020

Comprehensive Safety Review

11,000+ patients, 30+ trials; <1% serious adverse events.

2024